 The gene excision repair cross-complementing rodent repair deficiency complementation group 1 ERCC1 helps repair cell damage caused by satraplatin. It is possible that patients who have a variant of this gene will not benefit from treatment with satraplatin because the drug will not be able to damage the cancer cells effectively. 